Aurobindo Pharma Limited (AUROPHARMA)

Name: Aurobindo Pharma Limited（AUROPHARMA）— 财务报表历史
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

来自官方财务报表的收入、利润与现金流历史。

Healthcare · 华尔街（美国） · 最近更新： 2026-09-20

Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients for CNS, anti-retroviral, cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti-allergic therapeutic areas.

关键数据

市值: ₹998 billion
收入（截至 2026-03-31 财年）: ₹333.8B
净利润: ₹35.0B
毛利率: 57.1%
净利率: 10.5%

查看交互式图表与完整报表 →

年度利润表

利润表	2026-03-31	2025-03-31	2024-03-31	2023-03-31
总收入	₹333.8B	₹313.8B	₹287.0B	₹246.2B
毛利	₹190.6B	₹176.4B	₹154.7B	₹127.2B
营业利润（EBIT）	₹51.9B	₹50.5B	₹44.4B	₹25.4B
净利	₹35.0B	₹34.9B	₹31.7B	₹19.3B

来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。

资产负债表、现金流、季度数据与完整财务比率见 AUROPHARMA 交互式查看器。 /companies/us/AUROPHARMA

类似公司

本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。

English version →全部股票

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.